| 1. |
|
|
| 2. |
|
|
| 3. |
- Lundin, L-C, et al.
(författare)
-
Water policies (2nd edition)
- 2000
-
Ingår i: Sustainable Water Management in the Baltic Sea Basin. 3. River Basin management. - : The Baltic University Programme, Uppsala University. ; , s. 131-142
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
- Al-Khalili, F, et al.
(författare)
-
Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease : The Stockholm Female Coronary Risk Study
- 2000
-
Ingår i: American Heart Journal. - Karolinska Hosp & Inst, Dept Cardiol, Stockholm, Sweden. Karolinska Hosp & Inst, Dept Thorac Radiol, Stockholm, Sweden. Karolinska Hosp & Inst, Dept Publ Hlth Sci, Div Prevent Med, Stockholm, Sweden. : MOSBY-ELSEVIER. - 0002-8703 .- 1097-6744. ; 139:6, s. 971-978
-
Tidskriftsartikel (refereegranskat)abstract
- Background The objectives of this study were to investigate the relation between coronary risk factors, exercise testing parameters, and the presence of angiographically significant coronary artery disease (CAD) (>50% luminal stenosis) in female patients previously hospitalized for an acute CAD event. Methods and Results All women younger than age 66 years in the greater Stockholm area in Sweden who were hospitalized for acute coronary syndromes during a 3-year period were recruited, Besides collection of clinical parameters, coronary angiography and a symptom-limited exercise test were performed in 228 patients 3 to 6 months after the index hospitalization. The mean age was 56 +/- 7 years. Angiographically nonsignificant CAD (stenosis <50%) was verified in 37% of the patients; significant CAD was found in 63%. The clinical parameters that showed the strongest relation with the presence of significant CAD after adjusting for age were history of myocardial infarction (odds ratio [OR] 4.91, 95% confidence interval [CI] 2.35 to 7.49), history of diabetes mellitus (OR 3.83, 95% Cl 1.63 to 14.31), serum high-density lipoprotein cholesterol <1.4 mmol/L (OR 2.11, 95% Cl 1.20 to 3.72), and waist-to-hip ratio >0.85 (OR 1.78, 95% Cl 1.02 to 3.10). A low exercise capacity and associated low change of rate-pressure product from rest to peak exercise were the only exercise testing parameters that were significantly related to angiographically verified significant CAD (<90% of the predicted maximal work capacity adjusted for age and weight, OR 1.91, 95% CI 1.04 to 3.50). Conclusions In female patients recovering from unstable CAD, exercise capacity was the only exercise testing parameter of value in the prediction of significant CAD. The consideration of certain clinical characteristics and coronary risk factors offer better or complementary information when deciding on further coronary assessment.
|
|
| 14. |
- Al-Khalili, F, et al.
(författare)
-
Clinical predictors of poor outcome in women recovering from acute coronary syndrome
- 2000
-
Ingår i: Journal of the American College of Cardiology. - Karolinska Hosp, Dept Cardiol, S-10401 Stockholm, Sweden. Karolinska Hosp, Dept Publ Hlth Sci, Div Prevent Med, S-10401 Stockholm, Sweden. Karolinska Hosp, Dept Thorac Radiol, S-10401 Stockholm, Sweden. Karolinska Inst, Stockholm, Sweden. : ELSEVIER SCIENCE INC. - 0735-1097 .- 1558-3597. ; 35:2, s. 392A-392A
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 15. |
|
|
| 16. |
|
|
| 17. |
- Almbrand, B, et al.
(författare)
-
Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Results from the DIGAMI study
- 2000
-
Ingår i: European heart journal. - : Oxford University Press. - 1522-9645 .- 0195-668X. ; 21:9, s. 733-739
-
Tidskriftsartikel (refereegranskat)abstract
- Aims The aim of the present analysis was to estimate the cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus based on the results of the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. In this study 620 patients with diabetes mellitus and acute myocardial infarction were randomized to intense insulin treatment (insulin group) or to serve as controls given standard antidiabetic therapy. Mortality was significantly reduced in the insulin group. Methods and Results The cost-effectiveness ratio was estimated as the incremental cost per life-year and quality-adjusted life-year gained of intense insulin treatment. The incremental costs were estimated as the difference in health care costs and indirect costs (labour production) during the first year of follow-up plus the future costs of increased survival. The life-years gained were based on the 5-year long-term follow-up experience and an assumed annual 20% mortality risk for all patients thereafter. The health care costs were Euro 975 higher in the insulin group during the first year of follow-up, mainly due to a longer period of initial hospitalization related to the institution of multidose insulin. The estimated discounted gain in life-years of the insulin treatment was 0·94 years without and 0·66 with quality of life adjustment, respectively. The cost per life-year gained by intense insulin treatment was Euro 16900 and the cost per quality-adjusted life-year gained was Euro 24100. Thus the estimated cost-effectiveness ratios were relatively low. Conclusion The results of the DIGAMI study indicate that intense insulin treatment after an acute myocardial infarction in patients with diabetes mellitus has an acceptable level of cost-effectiveness.
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
|
|
| 25. |
|
|
| 26. |
|
|
| 27. |
|
|
| 28. |
|
|
| 29. |
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
|
|
| 33. |
|
|
| 34. |
|
|
| 35. |
|
|
| 36. |
|
|
| 37. |
|
|
| 38. |
|
|
| 39. |
|
|
| 40. |
|
|
| 41. |
|
|
| 42. |
|
|
| 43. |
|
|
| 44. |
|
|
| 45. |
|
|
| 46. |
|
|
| 47. |
- Kaczanowska, Magdalena, 1975-
(författare)
-
Study of the Link between Translation Termination and Ribosome Biogenesis
- 2004
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Release factor 1 (RF1) is a ribosome-binding protein required for termination of translation in Escherichia coli. To study the effect of slow termination on protein synthesis, two isolated suppressors to a temperature sensitive (Ts) mutant allele of RF1 were studied. The first mutation, rpsIt2215, located within the transcription terminator for the rplM operon, affects expression of ribosomal protein S9. This protein is part of the head domain of the small ribosomal subunit and facilitates mRNA accommodation during translation initiation. The second mutation is a small deletion of the initiation region of gene rimN. rimN141 leads to no production of functional protein, which in wild type is essential for 16S rRNA maturation. Still, even though the RimN protein contains a dsRNA-binding surface, it does not bind tightly to the ribosome. RimN’s probable function in 16S rRNA processing is to resolve and refold intermediate rRNA structures.Both rpsIt2215 and rimN141 affect maturation of 30S ribosomal subunit. The defect can be observed as a decrease in the amount of translating ribosomes, and as shown in the case of rimN141, also induced expression of rRNA. The affected 30S assembly and translation initiation might be part of the mutant RF1 suppression mechanism, acting through increased cellular RF1 concentrations or a decreased requirement for efficient termination.Not much is known about how the expression of RF1 is regulated. RF1 is encoded by the prfA gene, located as the second gene in the hemA operon. Three promoters have been suggested to regulate its transcription. Two of them, promoters P1hemA and P2hemA, are located upstream of hemA, the first gene in the operon. P1hemA is the stronger promoter and has been suggested to be regulated upon changes in growth rate and (p)ppGpp concentrations. However, our results do not support this view. The third promoter, PprfA, is putative and the +1 start site of transcription is located to the hemA-coding region.
|
|
| 48. |
|
|
| 49. |
|
|
| 50. |
|
|
